S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
NASDAQ:AMLX

Amylyx Pharmaceuticals - AMLX Stock Forecast, Price & News

$29.36
+11.46 (+64.02%)
(As of 09/8/2022 10:17 AM ET)
Add
Compare
Today's Range
$28.55
▼
$33.32
50-Day Range
$17.15
▼
$26.99
52-Week Range
$6.51
▼
$33.41
Volume
276,262 shs
Average Volume
1.08 million shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.8% Upside
$39.50 Price Target
Short Interest
Bearish
11.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.60) to ($0.53) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

682nd out of 1,091 stocks

Pharmaceutical Preparations Industry

326th out of 538 stocks

See Top Rated MarketRank™ Stocks Here
AMLX stock logo

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

September 8, 2022 | finance.yahoo.com
Amylyx ALS Drug Wins Backing of FDA Advisory Panel
September 8, 2022 | markets.businessinsider.com
Amylyx Pharma: FDA Advisory Committee Supports Approval Of AMX0035 For Treatment Of ALS
September 7, 2022 | bizjournals.com
FDA advisers give thumbs-up to ALS drug — with major caveat
September 7, 2022 | seekingalpha.com
Amylyx Pharma wins FDA advisory committee backing for ALS drug
September 7, 2022 | reuters.com
U.S. FDA panel votes for Amylyx's ALS drug
September 7, 2022 | finance.yahoo.com
UPDATE 2-Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround
September 7, 2022 | finance.yahoo.com
Controversial ALS Drug From Amylyx Gets Rare Second FDA Meeting
September 7, 2022 | finance.yahoo.com
FDA advisors give thumbs-up to ALS drug — with major caveat
September 7, 2022 | finance.yahoo.com
Amylyx’s ALS Drug Backed by FDA Advisers
September 7, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
September 6, 2022 | finance.yahoo.com
FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate
September 2, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
September 2, 2022 | finance.yahoo.com
The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff
August 29, 2022 | finance.yahoo.com
These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year
August 22, 2022 | nasdaq.com
Bullish insiders bet US$830k on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
July 29, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
July 18, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
July 5, 2022 | nasdaq.com
Amylyx Pharma: FDA Plans To Reconvene Advisory Committee To Review AMX0035 NDA On Sept. 7
July 5, 2022 | msn.com
U.S. FDA to reconvene experts' meeting for Amylyx ALS drug
July 5, 2022 | seekingalpha.com
Amylyx stock rises 8% as FDA panel sets September meeting to discuss ALS drug
July 5, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
July 5, 2022 | finance.yahoo.com
UPDATE 2-U.S. FDA to reconvene experts' meeting for Amylyx ALS drug
July 5, 2022 | finance.yahoo.com
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
July 5, 2022 | finance.yahoo.com
Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again
June 28, 2022 | finance.yahoo.com
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Company Calendar

Today
9/08/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
CUSIP
N/A
CIK
1658551
Web
amylyx.com
Phone
617-683-0917
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.50
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+34.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.96
Quick Ratio
7.96

Sales & Book Value

Annual Sales
$280,000.00
Price / Sales
6,137.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.68) per share
Price / Book
-10.96

Miscellaneous

Outstanding Shares
58,530,000
Free Float
51,099,000
Market Cap
$1.72 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Joshua CohenMr. Joshua Cohen (Age 30)
    Co-Founder, Co-CEO & Director
    Comp: $726.53k
  • Mr. Justin KleeMr. Justin Klee (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $726.53k
  • Mr. James M. Frates (Age 55)
    Chief Financial Officer
    Comp: $1.2M
  • Ms. Margaret M. Olinger M.B.A (Age 57)
    Global Head of Commercial & Chief Commercial Officer
    Comp: $567k
  • Ms. Gina M. Mazzariello (Age 51)
    Chief Legal Officer & Gen. Counsel
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 63)
    Global Head of HR & CHRO
  • Mr. Tom Holmes
    Global Head of Supply Chain
  • Dr. Patrick D. Yeramian M.D. (Age 63)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer
  • Mr. Chris Aiello
    Head of Canada & GM

Key Competitors

View All Competitors













AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price forecast for 2022?

5 Wall Street research analysts have issued 12-month target prices for Amylyx Pharmaceuticals' shares. Their AMLX share price forecasts range from $35.00 to $50.00. On average, they predict the company's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 120.7% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2022?

Amylyx Pharmaceuticals' stock was trading at $20.61 on January 1st, 2022. Since then, AMLX stock has decreased by 13.1% and is now trading at $17.90.
View the best growth stocks for 2022 here.

Are investors shorting Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 3,300,000 shares, a decrease of 9.8% from the July 15th total of 3,660,000 shares. Based on an average daily trading volume, of 917,700 shares, the short-interest ratio is presently 3.6 days. Approximately 11.2% of the shares of the stock are sold short.
View Amylyx Pharmaceuticals' Short Interest.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our AMLX earnings forecast.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

What is Amylyx Pharmaceuticals' stock symbol?

Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amylyx Pharmaceuticals' stock price today?

One share of AMLX stock can currently be purchased for approximately $17.90.

How much money does Amylyx Pharmaceuticals make?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.05 billion and generates $280,000.00 in revenue each year.

How can I contact Amylyx Pharmaceuticals?

The official website for the company is amylyx.com. The company can be reached via phone at 617-683-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 9/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.